226916-19-4 Usage
General Description
(E)-3-(1,4-DIOXASPIRO[4.5]DEC-7-EN-7-YL)ACRYLIC ACID, also known as spiro acrylate, is a chemical compound with a unique spirocycle structure. It is commonly used as a building block in the synthesis of various organic compounds and materials. The presence of the spirocycle structure gives (E)-3-(1,4-DIOXASPIRO[4.5]DEC-7-EN-7-YL)ACRYLIC ACID unique properties and reactivity, making it a valuable component in the development of novel pharmaceuticals, agrochemicals, and advanced materials. Its versatility and potential for modification make it a valuable tool for organic chemists and researchers working in drug discovery and material science.
Check Digit Verification of cas no
The CAS Registry Mumber 226916-19-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,6,9,1 and 6 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 226916-19:
(8*2)+(7*2)+(6*6)+(5*9)+(4*1)+(3*6)+(2*1)+(1*9)=144
144 % 10 = 4
So 226916-19-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H14O4/c12-10(13)4-3-9-2-1-5-11(8-9)14-6-7-15-11/h2-4H,1,5-8H2,(H,12,13)/b4-3+
226916-19-4Relevant articles and documents
Metabolism-based identification of a potent thrombin receptor antagonist
Clasby, Martin C.,Chackalamannil, Samuel,Czarniecki, Michael,Doller, Dario,Eagen, Keith,Greenlee, William,Kao, Grace,Lin, Yan,Tsai, Hsingan,Xia, Yan,Ahn, Ho-Sam,Agans-Fantuzzi, Jacqueline,Boykow, George,Chintala, Madhu,Foster, Carolyn,Smith-Torhan, April,Alton, Kevin,Bryant, Matthew,Hsieh, Yunsheng,Lau, Janice,Palamanda, Jairam
, p. 129 - 138 (2008/02/03)
The metabolism of our prototypical thrombin receptor antagonist 1, K i = 2.7 nM, was studied and three major metabolites (2, 4, and 5) were found. The structures of the metabolites were verified independently by synthesis. Compound 4 was shown
THROMBIN RECEPTOR ANTAGONISTS
-
Page 100, (2010/11/30)
Heterocyclic-substituted tricyclics of formula (I) or a pharmaceutically acceptable salt thereof, wherein: the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Q is optionally subs